AZN vs. ONC: AstraZeneca vs. BeOne Medicines Stock Comparison

Company Profile

AstraZeneca (AZN) and BeOne Medicines (ONC) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AZN is classified in Pharmaceuticals while ONC is classified in Biotechnology.

Both AstraZeneca (AZN) and BeOne Medicines (ONC) trade as ADRs — their core financials are comparable, but keep FX, depositary-program fees, and dividend withholding in view for each.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both AstraZeneca (AZN) at 22.57% and BeOne Medicines (ONC) at 18.40% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

For every dollar of sales, both AstraZeneca (AZN) at 17.68% and BeOne Medicines (ONC) at 13.86% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Both AstraZeneca (AZN) at 29.57% and BeOne Medicines (ONC) at 22.15% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both AstraZeneca (AZN) at 8.63% and BeOne Medicines (ONC) at 40.23% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: AstraZeneca (AZN) reports EPS growth of 45.33%, ranked against its industry; BeOne Medicines (ONC) has no EPS growth figure this period.

Growth Metrics

Financial Strength

BeOne Medicines (ONC) at 3.55 keeps current ratio within its industry’s typical mid-range, while AstraZeneca (AZN) at 1.01 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for AZN.

BeOne Medicines (ONC) at 0.35 carries an industry-typical debt-to-equity mix, while AstraZeneca (AZN) at 0.66 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

BeOne Medicines (ONC) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AstraZeneca (AZN) reports a yield of 1.73%, ranking against industry peers normally.

BeOne Medicines (ONC) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AstraZeneca (AZN) reports a payout of 45.38%, ranking against industry peers normally.

Dividend Metrics

Valuation

AstraZeneca (AZN) at 26.37 is near its industry’s usual P/E ratio, while BeOne Medicines (ONC) at 52.17 sits in the richer quartile — ONC needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both AstraZeneca (AZN) at 4.63 and BeOne Medicines (ONC) at 7.04 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

AstraZeneca (AZN) at 5.59 is valued about in line with its industry on P/B ratio, while BeOne Medicines (ONC) at 7.98 carries an above-peer premium to book — ONC is pricier on assets.

Valuation Metrics